AMRI Announces Proposal to Close UK-Based API Manufacturing Facility

ALBANY, New York, Feb. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today its intention, subject to consultation with its UK workforce, to close its UK facility in Holywell, Wales, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API).

"The original strategy for the Holywell site has been to act as a conduit between Europe and the United States. However, the site has not been able to do this in a way that maximises value for our customers and shareholders and is not aligned to the new strategic direction of the company," said William S. Marth, president and chief executive officer, AMRI. "We continue to move forward with our strategy to be the preeminent supplier of custom and complex end-to-end services to the pharmaceutical industry, which includes the development and manufacture of high-value, niche active pharmaceutical ingredients (APIs)."

The proposed closure of the U.K.-based operation may affect approximately 64 positions. The company is commencing consultation with employee representatives to consider ways of avoiding the proposed redundancies, reducing the number of redundancies and mitigating the impact of the redundancies. The company has no further information to provide at this stage, pending the outcome of consultation with its employees.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

About AMRI API Manufacturing
With demonstrated success in large scale API Manufacturing, we offer the preeminence and scale to support the chemical development and cGMP manufacture of complex Active Pharmaceutical Ingredients (API). Our global manufacturing footprint, which also includes manufacturing in Europe and India, provides customers with access to global markets and low-cost manufacturing of APIs or intermediates. In addition, we have the skills and infrastructure to adequately provide complex API research and development, analytical support and support with global regulatory activities.